4PF3
Mineralocorticoid receptor ligand-binding domain with compuond 37a
Summary for 4PF3
Entry DOI | 10.2210/pdb4pf3/pdb |
Descriptor | Mineralocorticoid receptor, 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one, 1,2-ETHANEDIOL, ... (4 entities in total) |
Functional Keywords | nuclear receptor, transcription factor, hypertension, non-steroidal antagonist, activating mutation, transcription-transcription inhibitor complex, transcription/transcription inhibitor |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 32578.57 |
Authors | Sogabe, S.,Habuka, N. (deposition date: 2014-04-28, release date: 2014-11-26, Last modification date: 2023-11-08) |
Primary citation | Hasui, T.,Ohyabu, N.,Ohra, T.,Fuji, K.,Sugimoto, T.,Fujimoto, J.,Asano, K.,Oosawa, M.,Shiotani, S.,Nishigaki, N.,Kusumoto, K.,Matsui, H.,Mizukami, A.,Habuka, N.,Sogabe, S.,Endo, S.,Ono, M.,Siedem, C.S.,Tang, T.P.,Gauthier, C.,De Meese, L.A.,Boyd, S.A.,Fukumoto, S. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists Bioorg.Med.Chem., 22:5428-5445, 2014 Cited by PubMed: 25187277DOI: 10.1016/j.bmc.2014.07.038 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.1 Å) |
Structure validation
Download full validation report